| III-01 Elin Boger Drug targeting in pulmonary sub-epithelial compartments predicted through systems pharmacology modelling Thursday 09:50-11:20 |
| III-02 Esther Encinas Application of modelling and simulation (M&S) methods within the context of a paediatric-use marketing authorisation (PUMA) application Thursday 09:50-11:20 |
| III-03 Elvira Erhardt Comparison of pharmacokinetic parameters estimated by the experimental R package 'nlmixr' and MONOLIX Thursday 09:50-11:20 |
| III-04 Ruben Faelens Clinical trial optimization of efficacy studies in slowly progressive diseases Thursday 09:50-11:20 |
| III-05 Kevin Feng Study and application of nonparametric and parametric population modeling for automatic subpopulation classification to CYP2D6 phenotype compounds and pediatric age groups Thursday 09:50-11:20 |
| III-06 Cecilia Fosser Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients Thursday 09:50-11:20 |
| III-07 Jose Francis Influence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients. Thursday 09:50-11:20 |
| III-08 Aline Fuchs Minimization of a utility function for optimizing the dosing frequency of amoxicillin administration in neonates according to a fixed PK/PD index Thursday 09:50-11:20 |
| III-09 Saskia Fuhrmann Model-based comparison of mAb clearance in pediatric populations* Thursday 09:50-11:20 |
| III-10 María García-Cremades Mechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer Thursday 09:50-11:20 |
| III-11 Iain Gardner A Whole body Physiologically based Pharmacokinetic Model for Antibody drug conjugates - model development and validation in rat Thursday 09:50-11:20 |
| III-13 Silke Gastine Population Pharmacokinetics of Micafungin in critically ill patients - evaluation of a fixed dose regimen Thursday 09:50-11:20 |
| III-14 Francois Gaudreault Circadian quantitative system pharmacology model to inform clinical study design and translation to human Thursday 09:50-11:20 |
| III-15 Parviz Ghahramani Antimicrobial Drug Development Common Practices in PK-PD Model Selection and Common Misconceptions Thursday 09:50-11:20 |
| III-16 Anais Glatard Varenicline exposure is associated with abstinence from smoking in a cohort of smokers from the general population Thursday 09:50-11:20 |
| III-17 Ignacio Gonzalez-Garcia Comparison of FO – FOCE population parameter estimation methods in PhysPK 2.0 against NONMEM 7.3 Thursday 09:50-11:20 |
| III-18 Sungwoo Goo Population pharmacokinetics(PK)/Pharmacodynamics(PD) modeling and simulation of vancomycin in pediatric infectious patients Thursday 09:50-11:20 |
| III-19 Verena Gotta Conceptual evaluation of urea rebound in pediatric hemodialysis patients by a physiology-based pharmacokinetic simulation study Thursday 09:50-11:20 |
| III-20 Sebastiaan Goulooze Kernel-based visual hazard comparison (kbVHC): a simulation-free diagnostic for parametric repeated time-to-event models Thursday 09:50-11:20 |
| III-21 Silvia Grandoni Evaluation of a minimal WB-PBPK platform supporting different routes of administration Thursday 09:50-11:20 |
| III-22 Ana-Marija Grisic Towards understanding the loss of response to infliximab in patients with inflammatory bowel disease: A population PK modelling approach Thursday 09:50-11:20 |
| III-23 Benjamin Guiastrennec Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human Thursday 09:50-11:20 |
| III-24 Monia Guidi Adequacy of open-loop Target Controlled Infusion devices during anesthesia Thursday 09:50-11:20 |
| III-25 Anubha Gupta Power calculation methods to detect covariates effect when combining observed and simulated data. Thursday 09:50-11:20 |
| III-26 Serge Guzy Population Pharmacokinetic of L-DOPA and its main metabolites: Use of the Phoenix based QRPEM algorithm Thursday 09:50-11:20 |
| III-27 Bengt Hamrén Pharmacokinetic and exposure-response analyses supporting ticagrelor dosing recommendation in patients with prior myocardial infarction (PEGASUS-TIMI 54) Thursday 09:50-11:20 |
| III-28 Nina Hanke Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug Thursday 09:50-11:20 |
| III-29 Niklas Hartung Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments Thursday 09:50-11:20 |
| III-30 Paul Healy Impact of metabolic polymorphism on the exposure to tramadol and its active metabolite in children Thursday 09:50-11:20 |
| III-31 Lee Heechan A population parmacokinetic analysis of fimasartan, a novel angiotensin-receptor antagonist, in healthy subjects and patients with hypertension Thursday 09:50-11:20 |
| III-32 Eleanor Howgate Sensitivity analysis of P-glycoprotein Ki values in dynamic DDI predictions Thursday 09:50-11:20 |
| III-33 Gailing Li Mechanism-Based Modeling In Chronic Heptatis B Thursday 09:50-11:20 |
| III-34 Moustafa M. A. Ibrahim Model-based diagnostics post-processing for fast automated model building; show-cased with residual error models and CWRES. Thursday 09:50-11:20 |
| III-35 Ibrahim Ince Extension of a pregnancy physiologically-based pharmacokinetic model for renally cleared drugs to the postpartum period Thursday 09:50-11:20 |
| III-36 Itziar Irurzun-Arana Population PD modelling of circulating biomarkers in patients with melanoma treated with interferon alpha2b Thursday 09:50-11:20 |
| III-37 Masoud Jamei Virtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package Thursday 09:50-11:20 |
| III-38 Candice Jamois Quantification of Anti-Drug-Antibodies (ADA) Impact on Drug Exposure Using a Population PK modeling Approach Thursday 09:50-11:20 |
| III-39 Julie Janssen Clinical trial simulations to optimize dose finding studies in paediatric oncology Thursday 09:50-11:20 |
| III-40 Jihyun Jeon Pharmacokinetic modeling of Donepezil after transdermal administration in rat Thursday 09:50-11:20 |
| III-41 Jin Jin Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Thursday 09:50-11:20 |
| III-42 Martin Johnson Exposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment Thursday 09:50-11:20 |
| III-43 Koen Jolling CHF5993 a triple combination therapy for COPD patients: population pharmacokinetic modelling of beclometasone-17-monopropionate (B17MP) following pMDI inhalation. Thursday 09:50-11:20 |
| III-44 Siv Jonsson Placebo and drug response assessment on Unified Parkinson’s Disease Rating Scale using longitudinal Item Response Modelling Thursday 09:50-11:20 |
| III-45 Matts Kågedal Herceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels. Thursday 09:50-11:20 |
| III-46 Vangelis Karalis On the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients Thursday 09:50-11:20 |
| III-47 Johannes Kast Antibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin Thursday 09:50-11:20 |
| III-48 Tatiana Khariton Human Population PK Model, Dose Selection and Target Attainment Simulations for CF-301 - a Novel Antibacterial Lysin Thursday 09:50-11:20 |
| III-49 Yu Kyong Kim Population Pharmacokinetic Model Development for Long-Acting Intramuscular Injection of Drug X in Healthy Subjects Thursday 09:50-11:20 |
| III-50 Yun Kim A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects Thursday 09:50-11:20 |
| III-51 Lena Klopp-Schulze Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis Thursday 09:50-11:20 |
| III-52 Frank Kloprogge Pharmacodynamics of vancomycin in children Thursday 09:50-11:20 |
| III-53 Ben Kluender Pharmacokinetic and Exposure-Response Analyses for Extrapolation of Efficacy of Adalimumab in Adolescent Patients with Hidradenitis Suppurativa Thursday 09:50-11:20 |
| III-54 Franziska Isabelle Kluwe Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy Thursday 09:50-11:20 |
| III-55 Jane Knöchel A novel measure of importance of state variables for model reduction: results for the blood coagulation network Thursday 09:50-11:20 |
| III-56 Gilbert Koch Characterization of heart rate and sleeping patterns in pre-term neonates Thursday 09:50-11:20 |
| III-57 Yuri Kosinsky Radiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach Thursday 09:50-11:20 |
| III-58 Pavel Kovalenko Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration Thursday 09:50-11:20 |
| III-59 Anu Shilpa Krishnatry Population pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors Thursday 09:50-11:20 |
| III-60 Anders Kristoffersson A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β-lactamase-Producing Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates Thursday 09:50-11:20 |
| III-61 Fabiola La Gamba A Bayesian PK/PD model for synergy; a case study Thursday 09:50-11:20 |
| III-62 Christian Laveille Population pharmacokinetics of Rimeporide: a sodium-hydrogen exchanger (NHE-1) inhibitor for patients with Duchenne Muscular Dystrophy (DMD) Thursday 09:50-11:20 |
| III-63 Silvia Maria Lavezzi Modelling of rituximab clearance reduction due to ibrutinib co-administration Thursday 09:50-11:20 |
| III-64 Jacob Leander Pharmacodynamic modeling of uric acid turnover and the effect of Verinurad (RDEA3170), a novel selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia Thursday 09:50-11:20 |
| III-65 Jong Bong Lee In silico modelling of chylomicron association to predict lymphatic absorption of small molecules Thursday 09:50-11:20 |
| III-66 Donghwan Lee Population pharmacokinetic analysis of meropenem in Korean patients with acute infections Thursday 09:50-11:20 |
| III-67 Jennifer Leohr A Semi-Physiologic Model of Postprandial Triglyceride Response following Anti-Obesity Therapy Thursday 09:50-11:20 |
| III-68 Sarah Lezzar Population pharmacokinetics and pharmacodynamics analysis of hydroxyurea, in adult patients with sickle cell anemia (SCA), and evaluation of disease markers Thursday 09:50-11:20 |
